Cash burn in the last financial year was ~$4.15m, suggestive of a 3.5 year cash runway, but costs will only increase as the company approaches and enters clinical trials in its CAR-T program.
Chimeric is currently in Phase 1 for its lead CAR-T therapy– its cash burn for the last half was ~$7m.
Another company in which I’m invested, PYC Therapeutics, is aiming to complete pre-clinical and commence Phase 1 on its lead program later this year. It's working through manufacturing, toxicology etc. at the moment. The last half year (H1 2022) R & D and corporate and admin spend was ~ $12.5m, up ~$5m on H1 2021 as the company works to complete the requirements for submission of an IND to commence Phase 1.
So, while I recognize that SYC is prudent in managing the company’s cash, I cannot see a cash burn of just $4m p.a. being sustained.
- Forums
- ASX - By Stock
- PTX
- PTX Media related
PTX Media related, page-334
-
- There are more pages in this discussion • 1,280 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.5¢ |
Change
-0.001(2.17%) |
Mkt cap ! $36.23M |
Open | High | Low | Value | Volume |
4.8¢ | 4.8¢ | 4.5¢ | $26.66K | 576.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 219999 | 4.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.9¢ | 114091 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 219999 | 0.045 |
2 | 239841 | 0.044 |
1 | 127800 | 0.043 |
5 | 204523 | 0.042 |
5 | 404266 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.049 | 114091 | 2 |
0.050 | 258635 | 6 |
0.053 | 18867 | 1 |
0.054 | 181093 | 3 |
0.055 | 75000 | 1 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |